Carrico J, Mellott CE, Talbird SE, Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program. Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Bailey DB, Raspa M, Bishop E, Mitra D, Wheeler A, Sacco P. Health and economic consequences of Fragile X syndrome for caregivers. J Dev Behav Pediatr. 2012 Nov 1;33(9):705-12.
Gittelman M, Brown TM, Holm-Larsen T, Persson BE. Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial. UroToday International Journal. 2011 Dec 1;4(6):Art. 81.
Dysktra LA, Granger AL. Interactions between the delta agonist SNC80, and the mu agonists, morphine, buprenorphine, and butorphanol in squirrel monkeys. Nida Res Monogr. 2000;180:65.
Gfroerer J, Lessler J, Parsley (Edwards) T. Studies of nonresponse and measurement error in the national household survey on drug abuse. Nida Res Monogr. 1997;167:273-95.